Ausgabe 1/2003
Inhalt (9 Artikel)
Original Papers
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor
C. François, M. Toumi, A.-M. Aakhus, K. Hansen
Original Papers
The assessment of the economic return from controlled clinical trials
D. Coyle, E. Grunfeld, G. Wells
Original Papers
The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden
P. Lindgren, B. Jönsson, J. DuChane
Original Papers
Implementing standardized cost categories within economic evaluations in musculoskeletal diseases
T. Mittendorf, S. Merkesdal, J. L. Huelsemann, J.-M. von der Schulenburg, H. Zeidler, J. Ruof
Original Papers
Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
G. Kobelt, L. Jönsson, S. Fredrikson
Pricing and Reimbursement Systems in Europe
Pricing and reimbursement of drugs in Denmark
K. Møller Pedersen
Editorial
The fourth hurdle as controlling instrument for expenditure on medication?
W. Kulp, W. Greiner, J.-M. von der Schulenburg